

Vigabatrin

PF-PTD-396

Synonyms

Clinical Indication

Vigabatrin is licensed for use as adjunctive therapy in patients with refractory partial seizures and for the treatment of infantile spasms. Vigabatrin is an antiepileptic drug which acts by irreversibly inhibiting gamma-aminobutyrate aminotransferase, the enzyme responsible for the breakdown of GABA. Vigabatrin blood levels are linearly related to drug dosage and there is little benefit in monitoring blood levels as a guide to dosage required

At present, serum Vigabatrin concentrations are useful in assessing compliance and evaluating risks of toxicity.

Its use has declined following the discovery of visual field defects in 30% of patients treated with the drug.

Part of Profile / See Also

Request Form

Combined Pathology manual blood form or ICE request. Note the duration of therapy, daily dose and time of last dose on the form.

Availability / Frequency of

Analysis

On request

Referred to Epilepsy Centre 8353

Turnaround Time

Weekly

Patient Preparation

Collect immediately before next dose due (trough level).

Sample Requirements

Specimen Type

Serum

Volume

1 mL

Container



Yellow (SST) tube.



Paediatric Yellow top (SST) tube

Reference Range & Units

2-36 mg/L

Interferences

Interpretation & Clinical

Decision Value (if applicable)

References

Test code

Lab Handling

